×
About 88 results

ALLMedicine™ Lung Cancer Chemotherapy Center

Research & Reviews  35 results

Combined effects of acupuncture and auricular acupressure for relieving cancer-related ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542116
Medicine Li H, Liu H

Oct 23rd, 2021 - Increasing attention has been paid to acupuncture and auricular acupressure as alternative strategies for cancer related fatigue (CRF) management. Therefore, we design this systematic review and meta-analysis to explore the efficacy and safety of ...

Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nest...
https://doi.org/10.1016/j.lungcan.2021.09.020
Lung Cancer (Amsterdam, Netherlands); Mody GN, Stover AM et. al.

Oct 12th, 2021 - Patients with lung cancer have high symptom burden and diminished quality of life. Electronic patient-reported outcome (PRO) platforms deliver repeated longitudinal surveys via web or telephone to patients and alert clinicians about concerning sym...

Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung ca...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477964
Drug Delivery; Yu XY, Jin X et. al.

Sep 28th, 2021 - Lung cancer is the second most common and lethal cancer in the world. Chemotherapy is the preferred treatment modality for lung cancer and prolongs patient survival by effective controlling of tumor growth. However, owing to the nonspecific delive...

Autophagy inhibition and microRNA‑199a‑5p upregulation in paclitaxel‑resistant A549/T l...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185510
Oncology Reports; Zeng T, Xu M et. al.

Jun 4th, 2021 - Multidrug resistance (MDR) is one of the major reasons for the clinical failure of cancer chemotherapy. Autophagy activation serves a crucial role in MDR. However, the specific molecular mechanism linking autophagy with MDR remains unknown. The re...

New Drug Protects Against Myelosuppression Secondary to Lung Cancer Chemotherapy.
https://doi.org/10.1097/01.NAJ.0000753640.11029.39
The American Journal of Nursing; Aschenbrenner DS

May 20th, 2021 - Trilaciclib (Cosela) is approved to protect normal bone marrow cells from damage secondary to chemotherapy in adults receiving a platinum-etoposide chemotherapy regimen or a topotecan chemotherapy regimen for extensive-stage small cell lung cancer.

see more →